Etherna, a Belgian developer of immunotherapies for the treatment of cancer and infectious diseases, has secured 34 million euros in Series B funding. The investors included LSP, PMV, Boehringer Ingelheim Venture Fund, Fund+ and Omega Funds.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: